HHS Public Access

Author manuscript

J Alzheimers Dis. Author manuscript; available in PMC 2024 April 11.

Published in final edited form as:

J Alzheimers Dis. 2020 ; 75(1): 157–172. doi:10.3233/JAD-200064.

Clinical and bacterial markers of periodontitis and their association with incident all-cause and Alzheimer's disease dementia in a large national survey

May A. Beydoun, PhD, MPH[1,*,†], **Hind A. Beydoun, PhD, MPH**[2], **Sharmin Hossain, PhD**[1], **Ziad W. El-Hajj, PhD**[3], **Jordan Weiss, MA**[4], **Alan B. Zonderman, PhD**[1]

[1]Laboratory of Epidemiology and Population Sciences, National Institutes on Aging, NIA/NIH/IRP, Baltimore, MD, USA.

[2]Fort Belvoir Community Hospital, Fort Belvoir, VA, USA.

[3]McGill University, Montreal, QC, Canada.

[4]Population Studies Center and the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.

Abstract

Microbial agents including periodontal pathogens have recently appeared as important actors in Alzheimer's Disease (AD) pathology. We examined associations of clinical periodontal and bacterial parameters with incident all-cause and AD dementia as well as AD mortality among U.S. middle-aged and older adults. Clinical [Attachment Loss (AL); probing pocket depth (PPD)] and bacterial [pathogen immunoglobulin G (IgG)] periodontal markers were investigated in relation to AD and all-cause dementia incidence and to AD mortality, using data from the third National Health and Nutrition Examination Surveys (NHANES III, 1988–1994) linked longitudinally with National Death Index and Medicare data through January 1st, 2014, with up to 26y of follow-up. Sex- and age-specific multivariable-adjusted Cox proportional hazards models were conducted. Among those ≥65y, AD incidence and mortality were consistently associated with PPD, two factors and one cluster comprised of *IgG* titers against Porphyromonas gingivalis (*P. gingivalis*), Prevotella melaninogenica (*P. melaninogenica*) and Campylobacter rectus (*C. rectus*) among others. Specifically, AD incidence was linked to a composite of *C. rectus* and *P. gingivalis*

[*]Corresponding author: May A. Beydoun, PhD, NIH Biomedical Research Center, National Institute on Aging, IRP, 251 Bayview Blvd., Suite 100, Room #: 04B118, Baltimore, MD 21224, baydounm@mail.nih.gov, Fax: 410-558-8236.
[†]MAB had full access to the data used in this manuscript and completed all the statistical analyses.

AUTHOR CONTRIBUTION:

May A. Beydoun: Study concept, plan of analysis, data management, statistical analysis, literature search, write-up of the manuscript, revision of the manuscript.
Hind A. Beydoun: Plan of analysis, literature search and review, write-up of parts of the manuscript, revision of the manuscript.
Sharmin Hossain: Plan of analysis, literature search and review, write-up of parts of the manuscript, revision of the manuscript.
Ziad El-Hajj: Literature search and review, write-up of parts of the manuscript, revision of the manuscript.
Jordan Weiss: Assistance with statistical analysis, write-up of parts of the manuscript, revision of the manuscript.
Alan B. Zonderman: Study concept, plan of analysis, write-up of parts of the manuscript, revision of the manuscript.

DECLARATION OF INTERESTS

All authors declare no conflict of interest. The views expressed in this article are those of the author(s) and do not reflect the official policy of the Department of the Army/Navy/Air Force, Department of Defense, or the U.S. Government.

Financial disclosure statement: Drs. Beydoun, Beydoun, Hossain, El-Hajj, Weiss, Zonderman declare no conflict of interest.

titers (per SD, aHR=1.22; 95% CI, 1.04–1.43, P=0.012), while AD mortality risk was increased with another composite (per SD, aHR=1.46; 95% CI, 1.09–1.96, P=0.017) loading highly on *IgG* for *P. gingivalis*, *Prevotella intermedia*, *Prevotella nigrescens*, *Fusobacterium nucleatum*, *C. rectus*, *Streptococcus intermedius*, *Capnocylophaga Ochracea* and *P. melaninogenica*. This study provides evidence for an association between periodontal pathogens and AD, which was stronger for older adults. Effectiveness of periodontal pathogen treatment on reducing sequelae of neurodegeneration should be tested in randomized controlled trials.

Keywords

Periodontal pathogens; periodontitis; dementia; Alzheimer's Disease; Aging

INTRODUCTION

Dementia, a common disorder affecting older adults, has an estimated prevalence of 4.7% (≥60y),[1] with 4.6–7.7 million additional annual cases occurring worldwide [3.5–10.5 per 1,000 in various world regions]. [1–3] Generally, ~60–80% of dementia is ascribed to Alzheimer's Disease (AD), [1] a progressive neurodegenerative disorder with a multi-factorial etiology. AD triggers progressive episodic memory deterioration followed by impairment in other domains of cognition.[4] AD is likely caused by age-dependent and progressive Aβ-amyloid brain deposition,[5] with a second pathological hallmark being the Neurofibrillary tangles (NFT) arising from hyper-phosphorylated tau proteins.[6] It constitutes the primary cause of disability among older adults[7], the leading health care burden in developed countries,[8] and the sixth leading cause of death in the US.[9] The number of AD-affected Americans is expected to rise from currently 5.4 million to 13.8 million by 2050.[9] In 2016, US long-term and hospice care cost for all-cause dementia (including AD, vascular dementia and other rare forms) was estimated at $236 billion.[9]

Despite no effective treatment, epidemiologic research has uncovered genetic markers for late-onset AD (e.g. ApoE *ε4*) and several modifiable risk factors. The combined effects of low education, smoking, physical inactivity, depression, mid-life obesity, hypertension and type 2 diabetes explains ~54% of AD risk,[10] leaving much variation unaccounted for. Identifying novel mid-life modifiable risk factors is essential for planning cost-effective interventions. Microbial agents have recently appeared as important actors of AD's etiology, [8] notably periodontal pathogens,[11–15] many of which can cause periodontitis (Pd), a condition shown to increase risk of diabetes, atherosclerosis, cardiovascular events, [16] and adverse cognitive outcomes.[11–15]

Pd affects 20–50% of older adults and is initiated by periodontal bacteria, the most well-known being *Porphyromonas gingivalis (P. gingivais), Tannerella forsythia (T. forsythia)*, *Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans)* and *Treponema denticola (T. denticola)*, triggering gingival inflammation, connective tissue destruction, periodontal pocket formation, alveolar bone loss and edentulation.[17] Given its increased prevalence with age, Pd may be highly predictive of AD. In fact, several hypothesized pathways link Pd to AD, including brain tissue invasion by periodontal gram-negative

bacteria found in the dental biofilm, release of bacterial byproducts into the brain via bloodstream invasion and direct impacts of peripheral nerves.[18] Periodontal pathogens can affect brain cytokines through systemic or neural pathways.[19] A recent comprehensive study suggests that *P. gingivalis* and its associated gingipains in the brain play a central role in AD pathogenesis and suggests that $A\beta_{1-42}$ is produced in the brain partly as a response to this infection.[20] However, the epidemiological evidence as to the relationship between various Pd-related pathogens, including *P. gingivalis*, and AD remains scarce.

We examined age and sex-specific associations of serum immunoglobulin G (IgG) humoral immune response against periodontal pathogens and Pd markers with incident all-cause and AD dementia as well as AD mortality among U.S. middle-aged and older adults (45+y at baseline) using the National Health and Nutrition Examination Survey (NHANES) III linked with Center for Medicare & Medicaid Services (CMS) data.

MATERIALS AND METHODS

Database: NHANES-CMS

The NHANES, sponsored by the National Center for Health Statistics (NCHS), consists of cross-sectional surveys providing nationally representative data on U.S. population health and nutritional status. Sampling follows a stratified, multistage probability cluster design. It includes in-home interviews for basic health and demographic information.[21] This was a retrospective cohort study whereby publicly available data was linked to restricted medical and death records and analyzed at the Research Data Center (RDC). CMS-Medicare and NDI linkage methodology is provided in Appendix I.

The present study was approved for ethical treatment of participants by the Institutional Review Board of the National Institute on Aging, Intramural Research Program.

Study Sample

A participant flowchart is presented in Figure 1, including the sample at risk and number of events. First, we included NHANES III participants aged 45+y with complete data on at least one of 19 periodontal pathogens Immunoglobulin G (*IgG)* humoral immune response (1988–1994, surplus serum, SPSDEPPX), mortality status and CMS-linkage data. Among 33,199 participants (aged 1–90 y) recruited in NHANES III (1988–1994) with complete socio-demographics (i.e., age and sex), 9,787 were aged 45+y, of whom 6,823 had complete surplus serum periodontal pathogen data.

Second, 4,672 participants aged 45+y had data on humoral immune response (*IgG*) against two periodontal pathogens only for phase 2 (1991–1994) of NHANES III (DEPP file), namely *Pg* and *Aa*. Of this sub-sample, 3,828 had complete data in the DEPP file (specifically on *Pg*). Sample sizes varied for both samples, depending on exposure of interest.

Participants without CMS-Medicare data were assumed to have no event of interest until end of 2013 or censored upon death. Thus, unweighted samples consisted of 6,823 participants with *Pg* measured at both phases and 3,828 with *P. gingivalis* measured at phase 2. After

exclusion due to Health Maintenance Organization (HMO) utilization, those samples were reduced to 6,650 and 3,749, respectively. Third, for PPD/AL exposures, the sample size was reduced to 5,088 (45+, both phases combined, CMS-Medicare exclusion) and PPD/AL exposures with complete both phase *P. gingivalis* and CMS-Medicare exclusion amounted to N=4,465.

Dementia and AD onset

The CMS Chronic Condition Data Warehouse Categories included a summary file with 21 chronic conditions and varying reference time periods, numbers and types of claims to qualify, exclusions and a set of International Classification of Diseases, version 9 (ICD-9)/ CPT4/HCPCS codes. AD was diagnosed using ICD-9 code 331.0 (any diagnosis on the claim) from inpatient, Skilled Nursing Patient [SNP], Home Health Agency [HHA], Health Options Program [HOP] or Carrier claims during a 3-year period. All-cause dementia was assessed using similar criteria with the following diagnostic codes: 331.0, 331.1, 331.11, 331.19, 331.2, 331.7, 290.0, 290.10, 290.11, 290.12, 290.13, 290.20, 290.21, 290.3, 290.40, 290.41, 290.42, 290.43, 294.0, 294.1, 294.10, 294.11, 294.8 and 797. We computed time-to-event starting from Medical Examination Center (MEC) examination date, using the earliest occurrence date. The summary file was available for 1999–2013 follow-up period. Using the same algorithm, we estimated AD/dementia's earliest diagnosis date during 1991–1998. [22] Follow-up time was truncated to January 1st, 2014 and was expressed in months.

Mortality from AD

AD mortality was a primary outcome and was determined using underlying cause of death ICD-10 code G30.[23] Additional AD cases were included when earliest AD diagnosis date was unavailable but AD-related death was assigned. Follow-up was censored at death or, if participants were alive by end of follow-up, Jan 1st 2014.

Dental examination and Clinical periodontal markers

Attachment loss (AL) and probing pocket depth (PPD) defined Pd in our study.[24] Briefly, dental examiners assessed oral health during both phases of MEC examinations in NHANES III. AL and PPD were measured at mid-buccal and mesio-buccal sites on every tooth in two randomly selected quadrants- the maxilla and the mandible (Range: 14–28 teeth).[25] AL was defined as distance between cemento-enamel junction and base of periodontal pocket, while PPD was distance from base of periodontal pocket to free gingival margin.[26] Mean AL and PPD were calculated for 28 sites. Two non-missing sites per tooth were required for AL/PPD measure and at least one tooth measurement was required to estimate the mean.[26]

Periodontal pathogens

Serum immunoglobulin G (IgG) titers were measured for humoral immune response against 19 periodontal bacteria using a series of 1:1,000 serum dilutions and checkerboard immunoblotting as previously described.[27] Those pathogens are: (1) *A. Actinomycetemcomitans* (American Type Culture Collection [ATCC] strains 43718, 29523, and 33384); (2) *P. gingivalis* (ATCC strains 3327 and 53978); (3) *T. forsythia* (ATCC strain 43037); (4) *T. denticola* (Oral Microbiology, Gothenburg, Sweden [OMGS] strain

3271); (5) *Campylobacter rectus* (*C. rectus*, ATCC strain 33238); (6) *Eubacterium nodatum* (*E. nodatum*, ATCC strain 33099); (7) *Prevotella intermedia* (*P. intermedia*, ATCC strain 25611); (8) *Prevotella nigrescens* (*P. nigrescens*, ATCC strain 33563); (9) *Prevotella melaninogenica* (*P. melaninogenica*, ATCC strain 25845); (10) *Fusobacterium nucleatum* (*F. nucleatum*, ATCC strain 33563); (11) *Parvimonas micra* aka *Micromonas micros* (*M. micros*, ATCC strain 10953); (12) *Selenomonas noxia* (*S. noxia*, ATCC strain 43541); (13) *Eikenella corrodens* (*E. corrodens*, ATCC strain 23834); (14) *Capnocylophaga ochracea* (*C. ochracea*, ATCC strain 33624); (15) *Streptococcus intermedius* (*S. intermedius*, ATCC strain 35037); (16) *Streptococcus oralis* (*S. oralis*, ATCC strain 35037); (17) *Streptococcus mutans* (*S. mutans*, ATCC strain 25175); (18) *Vellonella Parvula* (*V. parvula*, ATCC strain 10790); (19) *Actinomyces naeslundii* (*A. naeslundii*, ATCC strain 49340). [28] IgG titers were quantified using chemiluminescent signal-measuring instrument and compared to human IgG standard curve.[27] Specifically, 8,153 stored serums among NHANES III participants aged 40y or older were analyzed at Columbia University College of Dental Medicine, New York, NY between 2003 and 2006 (Phase 2 then Phase 1 samples). A factor analysis was conducted among individuals >45y of age, to extract independent common factors, using eigenvalue and scree plot criteria and varimax rotation (Appendix II). These factors were entered simultaneously into models examining associations between periodontal pathogens and AD mortality, AD incidence and all-cause dementia incidence. Finally, we created modified mutually-exclusive color-coded clusters that were determined using cluster analysis in a previous analysis of all available periodontal pathogen data (k=19, 40+y, NHANES III, both phases),[28] and analysis also used by others.[29] Those clusters were defined based on correlated Log_e transformed pathogen IgG titers as shown in Figure S1.[28] In our present study, we first summed Log_e transformed IgG to form the clusters of correlated pathogen titers. Those summation clusters were then z-scored to allow for better interpretation in our main models.

In phase 2 of NHANES III, 9,371 surplus sera on two periodontal pathogens were analyzed (*P. gingivalis* and *A. actinomycetemcomitans*) among participants aged 12y or older of whom 3,828 were 45+y. Antibody concentrations were measured in ELISA units of IgG (EU) and were examined in both untransformed and Log_e transformed metrics, for comparative purposes.

Covariates

Models were stratified by baseline age group (45+, 55+ and 65+) and sex. Demographic, socio-economic, social support, lifestyle and health-related factors, dietary quality and nutritional biomarkers were potential confounders included in all models (See Appendix II for details).

Statistical analysis

We performed analyses using Stata 15.0 (StataCorp, College Station, TX).[30] We accounted for survey design complexity by incorporating 6-yr (NHANES III, 1988–1994) and 3-yr (NHANES III, 1991–1994) primary sampling units and strata. Standard errors were estimated using Taylor series linearization (i.e. *svy*: commands).[30] Multivariate imputed data (m=5 imputations, 10 iterations) with chained equations [31] estimated means and

proportions across age groups and measures of association, after adjusting for sampling design complexity.

The main exposures of interest were 19 periodontal pathogens added simultaneously (Model 1) and separately (Model 2) for the entire NHANES III sample (1988–1994). Factors extracted from those 19 periodontal pathogens, as well as pre-determined color-coded clusters, were also considered as predictors of interest. For phase 2 NHANES III, *A. Actinomycetemcomitans* and *P. gingivalis* were main predictors, analyzed as standardized z-scores (as is and Log_e transformed). These periodontal pathogens were then entered as predictors (both phases and phase 2, separately) into linear regression models with periodontitis measured with AL and PPD as outcomes while adjusting for all covariates. Finally, means of AL/PPD were considered as separate predictors in main causal models, specifically incident AD and all-cause dementia due to smaller sample size for AD mortality outcome. In those models, defining time-to-event from any age≥45y since baseline visit (i.e. delayed entry) until death or censoring or outcome of interest (AD death, AD incidence, all-cause dementia incidence), we conducted Cox proportional hazards models for three outcomes stratifying separately by sex and baseline age to ≥45, ≥55 and ≥65y. We present fully adjusted models accounting for demographic, socio-economic, lifestyle/social support factors, nutritional biomarkers and health-related factors (Appendix II). Weighted mean times of follow-up are estimated from weighted person-months of follow-up and the weighted sample in each model ($[\text{Person-months}_{(\text{weighted})}]/[\text{Persons}_{(\text{weighted})}]$). A type I error of 0.05 was considered for statistical significance and 0.10 for borderline (or marginal) significance. Multiple testing adjustment was done using a familywise Bonferroni approach while accounting for outcome multiplicity (e.g. AL/PPD: 2 outcomes; incident AD/all-cause dementia/AD mortality: 3 outcomes) and assuming that each exposure, model and strata was a distinctive hypothesis.[32]

RESULTS

Participant characteristics by age group and sex

Cumulative incidence (weighted) of all three outcomes increased linearly with baseline age, with AD dementia, all-cause dementia and AD mortality reaching 18%, 38% and 3% in the 65+ baseline age group, respectively. Women in this sample were more likely to be older, and baseline age was also directly related to Non-Hispanic white race, smaller household size, higher proportion widowed, larger means of AL and PPD, and higher proportions completely or partially edentulous (Tables 1 and S1). However, most periodontal pathogen titers were either unrelated or inversely linked to age, with the clearest inverse relationship shown for Orange Blue and Yellow Orange clusters, and for *Factor 3* comprised of *E. nodatum* and *A. naeslundii IgG* titers. Moreover, socio-economic status was associated with younger age, while age was directly related to better dietary quality as measured by the 1995 Healthy Eating Index, co-morbidity and AL, reduced physical activity, smoking and drug use, lower prevalence of obesity, reduced mean of 25(OH)D coupled with increased levels of folate, vitamin A, vitamin E, total carotenoids and ferritin.

Periodontal pathogens' association with AD mortality, AD and all-cause dementia incidence

After correction for multiple testing (Table 2), Phase 2 *P. gingivalis IgG* titers (un-transformed, z-scores) were associated with increased risk for incident AD dementia, particularly among women (1 SD=212, HR=1.14, 95% CI: 1.05–1.23, P=0.004) and individuals above 55 (HR=1.06) or 65y (HR=1.12) at baseline. Log_e transformed *P. gingivalis IgG* titers were marginally associated with increased risk for AD mortality in 65+ age group, while the reverse was true for *A. Actinomycetemcomitans* IgG (both transformed and untransformed, 65+). When examining all 19 periodontal pathogens (Log_e transformed, z-scored, 1988–1994) in relation to the three dementia outcomes of interest (Tables S2 and 3), and upon multiple testing adjustment, we found that *S. oralis IgG* was linked with increased risk for all-cause dementia among men, a pattern observed among women for *E. corrodens IgG* (*Model 1*: all pathogens entered). Similarly, *C. rectus IgG* was associated with increased risk for all-cause dementia in all age groups, a pattern that was consistent between models 1 and 2 among the older group (65+). *C. rectus IgG* was also marginally and directly associated with incident AD risk in the 55+ age group (Model 1), while *S. intermedius* was marginally and inversely associated with incident AD risk among women (Model 1). For AD mortality (Table 3), most of our findings emerged when each periodontal pathogen was entered separately into the model (*Model 2*). Most notably, *P. gingivalis IgG* (Log_e transformed, z-score) was associated with increased AD mortality risk among those aged 65+ at baseline (1 SD=2.03, HR=1.36, 95% CI: 1.10–1.69, P=0.010), as was the case for *P. melaninogenica IgG* (1 SD=1.28, HR=1.43, 95% CI: 1.11–1.85, P=0.009). The latter finding was further strengthened by adding the remaining 18 titers into the model (HR=1.73, P=0.005). Consistent with all-cause dementia (Table S2), Table 3 also indicates that *So* was directly related to AD mortality risk among men (Model 2). Additionally, AD mortality risk was increased with higher *S. intermedius IgG*.

Periodontal pathogen factor and clusters and their association with AD mortality, AD and all-cause dementia incidence

Using factor analysis and pre-defined clusters (Table 4), our results indicated that AD incidence was associated with *Factor 4* in the 65+ age group, which loaded highly on *C. rectus* and *P. gingivalis* titers (aHR=1.22; 95% CI, 1.04–1.43, P=0.012). In this model, the effect of 1 SD increase in *Factor 4* on AD incidence was equivalent to two years of aging on the Log_e(HR) scale. Moreover, AD mortality risk was increased with higher baseline Factor 2 in that age group (per SD, aHR=1.46; 95% CI, 1.09–1.96, P=0.017) which loaded highly on *P. gingivalis*, *P. intermedia*, *P. nigrescens*, *F. nuclatum*, *C. rectus*, *S. intermedius*, *C. ochracea* and *P. melaninogenica* titers. In both 55+ and 65+ age group, Orange-Red cluster (*P. melaninogenica* , *P. intermedia* , *P. nigrescens* , *P. gingivalis*) was associated with increased AD mortality risk, while Red-Green cluster (*T. forsythia*, *T. denticola*, *A. actinomycetemcomitans* , *E. corrodens*, *S. noxia*, *V. parvula*, *C. rectus*) was only marginally associated with AD and all-cause dementia among women (P<0.033), after correction for multiple testing.

Clinical Pd markers and their association with periodontal pathogens and AD/all-cause dementia outcomes

Moreover, *P. gingivalis IgG*, the Orange-Red, Red-Green and Yellow-Orange clusters, Factors 2 and 4 were independently associated with clinical Pd markers (AL/PPD) (Table S3). Nevertheless, only a marginal association between PPD and incident AD risk was detected among men and older individuals upon multiple testing adjustment (Table S4).

DISCUSSION

To our knowledge, this is the first large retrospective cohort study to examine the association between periodontal pathogens (and measures of Pd: AL/PPD) with AD incidence and mortality and incident all-cause dementia. Our findings indicated that IgG against *P. gingivalis, P. melaninogenica* and *C. rectus*, two empirical periodontal pathogen factors, and two empirical periodontal pathogen clusters as well as PPD were consistently linked with at least one of the 3 outcomes among older adults. Moreover, findings with all-cause dementia and not AD pertained mostly to the outcome of vascular dementia, given that it is the second most common cause of dementia.

Although there are no other studies examining the association between periodontal pathogens and incidence of dementia per se, several studies have examined the relations between periodontal pathogens and cognitive impairments that could yield dementia outcomes. Our findings of positive associations between Pd and periodontal pathogens with various dementia outcomes mirror previous findings with cognitive outcomes. Specifically, using NHANES III, a study found that the highest *Pg* IgG (119 ELISA Units [EU]) were more likely to exhibit poor delayed verbal recall (OR 2.89, 95% CI 1.14 to 7.29) and impaired subtraction (OR 1.95, 95% CI 1.22 to 3.11).[13] Two other nested case-control studies of periodontal pathogens found that participants with elevated *A. naeslundii* IgG (0.640 ng/ml) level exhibited higher risk of AD, [14] as did titers for *F. nucleatum* and *P. intermedia*.[15] Similarly, the risk of developing dementia was higher among Pd patients compared to controls (HR = 1.16, 95% CI= 1.01–1.32, P=0.03).[33] Nevertheless, recent reviews and meta-analyses examining pooled evidence on Pd and dementia came to different conclusions.[12] This discrepancy highlights the need to examine associations between periodontal pathogens with AD and other types of dementia within different sub-groups (preferably at different baseline ages), as was done in our present study. Furthermore, our study indicated that PPD, a measure of current periodontitis was associated with incident AD among older adults, though that was not the case of AL, a measure of cumulative exposure. This finding needs to be replicated in other comparable cohorts.

Suggested mechanisms linking Pd or periodontal pathogens with cognitive impairment and dementia are still speculative. First, bacterial pathogens can spread from periodontal regions to blood stream into other bodily organs. Second, toxins produced by pathogens can damage the vascular system via oxidative stress leading to atherosclerosis which may trigger dementia or stroke.[12] Third, inflammatory mediators of Pd including cytokines, chemokines and prostaglandins can contribute to AD by triggering brain inflammation. [19] *P. gingivalis* and *P. melaninogenica* are related rod-shaped, black-pigmented, strictly anaerobic gram-negative bacteria. [18] Perhaps the most characteristic feature of *P.*

gingivalis induced periodontitis is the production of gingipains, enzymes that can cleave proteins specifically after arginine or lysine amino acids,[34] and which are secreted through a complex known as Type IX Secretion System (T9SS) protein secretion system.[34] Gingipains target host peptides with antimicrobial or anti-inflammatory activities, and by inactivating them induce edema and bleeding, in addition to allowing bacterial cells to infiltrate neutrophils.[35] Together with other virulence factors, this allows *P. gingivalis* to induce inflammation while evading host immune response,[36] and to make use of inflammatory fluids as a source of essential nutrients (e.g. iron)[37] required for bacterial growth.[38] *P. gingivalis* produces proteolytic enzymes that target immunoglobulins and cell surface adhesion proteins, which could facilitate invasion and weaken host immune resp Mouse models show that the lipopolysaccharides (LPS) and the gingipains produced by *Pg* respectively increase accumulation of Amyloid β (Aβ) [20, 39] and enhance migration and inflammation of microglia,[40] which are two hallmark pathologies of AD. Recent mouse studies have demonstrated that repeated exposure to *P. gingivalis* resulting in gingipain accumulation in and around brain cells, was responsible for neurodegeneration and strongly correlated with hippocampal Aβ accumulation.[20, 41] onset.[42] Importantly, Poole et al. confirmed in an in vitro study of AD brain tissue and controls that that LPS from periodontal bacteria can access the AD brain during life given that labeling in the matched controls was absent. This demonstration of a known chronic oral-pathogen-related virulence factor reaching the human brains suggests an inflammatory role in the existing AD pathology. [43] Moreover, Dominy et. al have found that small-molecule inhibitors of gingipains may be an effective treatment against *P. gingivalis*-induced brain inflammation and bacterial colonization and thus may slow neurodegeneration.[20] The present study adds to the epidemiological evidence suggesting that *P. gingivalis* eradication among others may be an effective means to delay onset of AD, pending randomized clinical trials.

Just like *P. gingivalis* , *P. melaninogenica* expresses a complete T9SS secretion system. Although *P. melaninogenica* does not use gingipains, T9SS is important in biofilm formation and is involved in Pd, possibly by secreting proteases.[44] Our results indicate that *Pg* and *Pm* may independently or interactively induce cognitive impairment leading to AD as an underlying cause of death among older adults.

Moreover, another study showed that *P. gingivalis* LPS alone was sufficient to antagonize IL-6 and IL-8, but not IL-1β stimulation by another pathogen, namely *C. rectus*, suggesting that mixed infections, particularly interactions between *P. gingivalis* and *C. rectus* may impair host immune responses through cytokine level reduction of direct relevance to both periodontitis and AD. [45]

Our study has several notable strengths including the use of a large, nationally representative sample, inclusion of middle-aged adults (≥45y), assessment of AD incidence and mortality and incident all-cause dementia over a long follow-up period of up to 26y, measurement of serum antibody levels for periodontal pathogens combined with dental examination and adjustment for key potential confounders.

Limitations include observational study design, even though temporality of associations were ascertained. Underdiagnosis of AD and other dementias is a possibility despite the

fact that over 90% of the US population is eligible for and uses Medicare after the age of 65y and that the linkage was comprehensive, including all aspects of health care utilization (e.g. inpatient and outpatient) with continuous follow-up between 1991 and 2014. Nevertheless, a few cases missed by Medicare were added using NDI to assess incident AD and all-cause dementia. Moreover, the data lacked some key biochemical biomarkers of AD (such as blood or CSF markers of Aβ and tau) and neuroimaging of patients. Additionally, clinical periodontal measures were only estimated based on partial-mouth examination. This could underestimate Pd severity, thus attenuating observed associations. An in-depth study examining other alternative measures of clinically defined categories for periodontitis may be warranted. Furthermore, serum *IgG* humoral immune response exposures, though normalized through Log_e transformation, exhibited moderate collinearity. Finally, residual confounding bias particularly by genetic risk factors (e.g. ApoE4 status) cannot be discounted.

This study provides evidence for an association between periodontal pathogens and AD, which was stronger for older adults and calls for a line of inquiry, including randomized controlled trials, on the effectiveness of periodontal treatment against onset and progression of neurodegenerative disorders such as AD.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENT

The authors would like to thank Mr. Negasi Beyene (CDC/NCHS/RDC) and Mr. Ray Kuntz (AHRQ) for their help with access to the restricted data at the RDC and facilitating data analysis at the AHRQ headquarters, Rockville, MD. We would also like to thank Ms. Megan Williams and Ms. Nicolle Mode (NIA/NIH/IRP) for internally reviewing our manuscript.

Sources of funding:

This study was entirely supported by the National Institute on Aging, Intramural Research Program (NIA/NIH/IRP).

ABBREVIATIONS

25(OH)D
25-hydroxyvitamin D

A. Actinomycetemcomitans
Aggregatibacter Actinomycetemcomitans

AD
Alzheimer’s disease

aHR
Adjusted Hazard Ratio

Aβ

Amyloid β

A. naeslundii
Actinomyces Naeslundii

ApoE
Apolipoprotein E

ATCC
American type culture collection

BMI
Body Mass Index

AL
Attachment loss

CDC
Centers for Disease Control and Prevention

CMS
Center for Medicare & Medicaid Services

C. ochracea
Capnocylophaga Ochracea

C. rectus
Campylobacter Rectus

E. corrodens
Eikenella corrodens

ELISA
Enzyme Linked Immunosorbent Assay

E. nodatum
Eubacterium Nodatum

ESRD
End-Stage Renal Disease

EU
ELISA units

FFS
Fee for service

F. nucleatum
Fusobacterium Nucleatum

HEI
Healthy Eating Index

HHA
Home Health Agency

HMO
Health Maintenance Organizations

HOP
Health Options Program

HR
Hazard Ratio

HS
High School

ICD
International Classification for Disease, version 9

IgG
Serum immunoglobulin G

LPS
Lipo-polysaccharide

MAR
Mean Adequacy Ratio

MEC
Medical Examination Center

M. micros
Micomonas Micros

NCHS
National Center for Health Statistics

NDI
National Death Index

NFT
Neurofibrillary tangles

NHANES
National Health and Nutrition Examination Surveys

Pd
Periodontitis

PFFS
Private Fee-For-Service

P. gingivalis
Porphyromonas Gingivalis

P. intermedia
Prevotella Intermedia

Pm
Prevotella Melaninogenica

P. nigrescens
Prevotella Nigrescens

S. intermedius
Streptococcus Intermedius

S. mutans
Streptococcus Mutans

S. noxia
Selenomonas Noxia

SNP
Skilled Nurse Practitioner

So
Streptococcus Oralis

SPSDEPPX
Antibodies to Periodontal Pathogens

SSN
Social Security Number

T9SS
Type IX secretion system

T. denticola
Treponema Denticola

T. forsythia
Tannerella forsythia

V. parvula
Vellonella Parvula

REFERENCES

[1]. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ (2012) Epidemiology of dementias and Alzheimer's disease. Arch Med Res 43, 600–608. [PubMed: 23159715]

[2]. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer's Disease I (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117. [PubMed: 16360788]

[3]. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9, 63–75 e62. [PubMed: 23305823]

[4]. Lindeboom J, Weinstein H (2004) Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer's disease, and vascular cognitive impairment. Eur J Pharmacol 490, 83–86. [PubMed: 15094075]

[5]. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356. [PubMed: 12130773]

[6]. Turner RS (2003) Biomarkers of Alzheimer's disease and mild cognitive impairment: are we there yet? Exp Neurol 183, 7–10. [PubMed: 12957483]

[7]. Helmer C, Pasquier F, Dartigues JF (2006) [Epidemiology of Alzheimer disease and related disorders]. Med Sci (Paris) 22, 288–296. [PubMed: 16527211]

[8]. Honjo K, van Reekum R, Verhoeff NP (2009) Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement 5, 348–360. [PubMed: 19560105]

[9]. Alzheimer's A (2016) 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12, 459–509. [PubMed: 27570871]

[10]. Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10, 819–828. [PubMed: 21775213]

[11]. Cestari JA, Fabri GM, Kalil J, Nitrini R, Jacob-Filho W, de Siqueira JT, Siqueira SR (2016) Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease and Mild Cognitive Impairment Compared with Controls. J Alzheimers Dis 52, 1479–1485. [PubMed: 27104907]

[12]. Maldonado A, Laugisch O, Burgin W, Sculean A, Eick S (2018) Clinical periodontal variables in patients with and without dementia-a systematic review and meta-analysis. Clin Oral Investig.

[13]. Noble JM, Borrell LN, Papapanou PN, Elkind MS, Scarmeas N, Wright CB (2009) Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III. J Neurol Neurosurg Psychiatry 80, 1206–1211. [PubMed: 19419981]

[14]. Noble JM, Scarmeas N, Celenti RS, Elkind MS, Wright CB, Schupf N, Papapanou PN (2014) Serum IgG antibody levels to periodontal microbiota are associated with incident Alzheimer disease. PLoS One 9, e114959. [PubMed: 25522313]

[15]. Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, Dawson D 3rd (2012) Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement 8, 196–203. [PubMed: 22546352]

[16]. Leira Y, Dominguez C, Seoane J, Seoane-Romero J, Pias-Peleteiro JM, Takkouche B, Blanco J, Aldrey JM (2017) Is Periodontal Disease Associated with Alzheimer's Disease? A Systematic Review with Meta-Analysis. Neuroepidemiology 48, 21–31. [PubMed: 28219071]

[17]. Pihlstrom BL, Michalowicz BS, Johnson NW (2005) Periodontal diseases. Lancet 366, 1809–1820. [PubMed: 16298220]

[18]. Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M, de Leon MJ (2008) Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. J Alzheimers Dis 13, 437–449. [PubMed: 18487851]

[19]. Kamer AR, Craig RG, Dasanayake AP, Brys M, Glodzik-Sobanska L, de Leon MJ (2008) Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement 4, 242–250. [PubMed: 18631974]

[20]. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa

B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J (2019) Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 5, eaau3333. [PubMed: 30746447]

[21]. Center for Disease Control and Prevention (CDC) (1996) Centers for Disease Control and Prevention.

[22]. Center for Disease Control and Prevention, NHANES and CMS Linked Data Overview, https://www.cdc.gov/nchs/tutorials/NHANES-CMS/Orientation/Overview/index.htm,

[23]. National Center for Health Statistics DL (2015).

[24]. Choi YH, McKeown RE, Mayer-Davis EJ, Liese AD, Song KB, Merchant AT (2011) Association between periodontitis and impaired fasting glucose and diabetes. Diabetes Care 34, 381–386. [PubMed: 21216848]

[25]. Statistics NCfH, Plan and operation of the third National Health and Nutrition Examination Survey,1988–1994. Series 1: Programs and No. 32 Collection Procedures , http://www.cdc.gov/nchs/data/series/sr_01/sr01_032.pdf,

[26]. Choi YH, McKeown RE, Mayer-Davis EJ, Liese AD, Song KB, Merchant AT (2014) Serum C-reactive protein and immunoglobulin G antibodies to periodontal pathogens may be effect modifiers of periodontitis and hyperglycemia. J Periodontol 85, 1172–1181. [PubMed: 24410292]

[27]. Papapanou PN, Neiderud AM, Sandros J, Dahlen G (2001) Checkerboard assessments of serum antibodies to oral microbiota as surrogate markers of clinical periodontal status. J Clin Periodontol 28, 103–106. [PubMed: 11142661]

[28]. Shrestha D, Choi YH, Zhang J, Hazlett LJ, Merchant AT (2015) Relationship between serologic markers of periodontal bacteria and metabolic syndrome and its components. J Periodontol 86, 418–430. [PubMed: 25415246]

[29]. Desvarieux M, Demmer RT, Jacobs DR Jr., Rundek T, Boden-Albala B, Sacco RL, Papapanou PN (2010) Periodontal bacteria and hypertension: the oral infections and vascular disease epidemiology study (INVEST). J Hypertens 28, 1413–1421. [PubMed: 20453665]

[30]. STATA (2017) Stata Corporation, Texas.

[31]. Lee KJ, Carlin JB (2010) Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol 171, 624–632. [PubMed: 20106935]

[32]. Hochberg Y, Tamhane AC, (1987) Multiple comparison procedures, Wiley, New York.

[33]. Lee YT, Lee HC, Hu CJ, Huang LK, Chao SP, Lin CP, Su EC, Lee YC, Chen CC (2017) Periodontitis as a Modifiable Risk Factor for Dementia: A Nationwide Population-Based Cohort Study. J Am Geriatr Soc 65, 301–305. [PubMed: 27685603]

[34]. Potempa J, Sroka A, Imamura T, Travis J (2003) Gingipains, the major cysteine proteinases and virulence factors of Porphyromonas gingivalis: structure, function and assembly of multidomain protein complexes. Curr Protein Pept Sci 4, 397–407. [PubMed: 14683426]

[35]. Sochalska M, Potempa J (2017) Manipulation of Neutrophils by Porphyromonas gingivalis in the Development of Periodontitis. Front Cell Infect Microbiol 7, 197. [PubMed: 28589098]

[36]. Tada H, Nishioka T, Takase A, Numazaki K, Bando K, Matsushita K (2019) Porphyromonas gingivalis induces the production of interleukin-31 by human mast cells, resulting in dysfunction of the gingival epithelial barrier. Cell Microbiol 21, e12972. [PubMed: 30423602]

[37]. Hajishengallis G (2011) Immune evasion strategies of Porphyromonas gingivalis. J Oral Biosci 53, 233–240. [PubMed: 22162663]

[38]. Olczak T, Simpson W, Liu X, Genco CA (2005) Iron and heme utilization in Porphyromonas gingivalis. FEMS Microbiol Rev 29, 119–144. [PubMed: 15652979]

[39]. Ishida N, Ishihara Y, Ishida K, Tada H, Funaki-Kato Y, Hagiwara M, Ferdous T, Abdullah M, Mitani A, Michikawa M, Matsushita K (2017) Periodontitis induced by bacterial infection exacerbates features of Alzheimer's disease in transgenic mice. NPJ Aging Mech Dis 3, 15. [PubMed: 29134111]

[40]. Liu Y, Wu Z, Nakanishi Y, Ni J, Hayashi Y, Takayama F, Zhou Y, Kadowaki T, Nakanishi H (2017) Infection of microglia with Porphyromonas gingivalis promotes cell migration and an

inflammatory response through the gingipain-mediated activation of protease-activated receptor-2 in mice. Sci Rep 7, 11759. [PubMed: 28924232]

[41]. Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragozzino ME, Le K, Aljewari HW, O'Brien-Simpson NM, Reynolds EC, Watanabe K (2018) Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One 13, e0204941. [PubMed: 30281647]

[42]. Grenier D, Mayrand D, McBride BC (1989) Further studies on the degradation of immunoglobulins by black-pigmented Bacteroides. Oral Microbiol Immunol 4, 12–18. [PubMed: 2628862]

[43]. Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S (2013) Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J Alzheimers Dis 36, 665–677. [PubMed: 23666172]

[44]. Kondo Y, Sato K, Nagano K, Nishiguchi M, Hoshino T, Fujiwara T, Nakayama K (2018) Involvement of PorK, a component of the type IX secretion system, in Prevotella melaninogenica pathogenicity. Microbiol Immunol 62, 554–566. [PubMed: 30028034]

[45]. Bostanci N, Allaker RP, Belibasakis GN, Rangarajan M, Curtis MA, Hughes FJ, McKay IJ (2007) Porphyromonas gingivalis antagonises Campylobacter rectus induced cytokine production by human monocytes. Cytokine 39, 147–156. [PubMed: 17709256]



FIGURE 1.

Participant Flowchart

Note: Both phases: 1988–1994; Phase 2: 1991–1994

Abbreviations: AD=Alzheimer's Disease; CMS=Centers for Medicare and Medicaid Services; NHANES III=Third National Health and Nutrition Examination Surveys.

TABLE 1.

Baseline characteristics of selected participants by age group, NHANES III, 1988–1994 [N=3,749 (phase 2: 1991–1994); N=6,650 (both phases)][a]

Selected participant characteristics	Age group (y)			P-value* (Design-based F-test)[b]	
	45–55	55–65	65+		
Unweighted N (both phases)	(N=1,701) 25.6%	(N=1,698) 25.5%	(N=3,251) 48.9%	55–65 vs. 45–55	65+ vs. 45–55
Cumulative incidence of AD and all-cause dementia and of AD mortality, weighted %					
AD dementia	1.7±0.3	11.2±1.1	18.3±0.9	<0.001	<0.001
All-cause dementia	4.3±0.5	18.9±1.3	37.5±1.1	<0.001	<0.001
AD mortality	0.1±0.1	1.1±0.4	2.9±0.4	0.028	0.001
Dental measures					
Periodontitis, mean±SE	(N=1,435)	(N=1,225)	(N=1,805)		
Attachment Loss	1.45±0.05	1.76±0.07	1.98±0.07	0.03	<0.001
Probing Pocket Depth	1.50±0.03	1.53±0.04	1.45±0.03	0.29	0.28
Factors (z-scores), mean±SE	(N=1,597)	(N=1,604)	(N=3,077)		
Factor 1	−0.05±0.09	+0.00±0.09	0.02±0.08	0.35	0.24
Factor 2	−0.05±0.04	−0.09±0.04	−0.15±0.04	0.46	0.063
Factor 3	+0.21±0.04	+0.13±0.04	−0.04±0.03	0.10	<0.001
Factor 4	−0.07±0.06	−0.15±0.04	−0.09±0.04	0.09	0.62
Factor 5	+0.05±0.07	−0.04±0.05	+0.03±0.04	0.12	0.84
Clusters (z-scores), mean±SE	(N=1,655)	(N=1,655)	(N=3,169)		
Orange Red	−0.097±0.04	−0.150±0.040	−0.183±0.036	0.35	0.078
Red Green	−0.031±0.010	−0.071±0.085	−0.046±0.071	0.55	0.83
Yellow Orange	+0.02±0.06	−0.02±0.06	−0.10±0.05	0.51	0.020
Orange Blue	+0.19±0.04	+0.10±0.05	−0.10±0.04	0.08	<0.001
Dentate status	(N=1,701)	(N=1,698)	(N=3,251)		
Completely edentulous	9.2±1.11	19.0±1.24	32.2±1.87	—	—
Edentulous in one arch	10.5±1.22	14.5±1.07	14.8±0.95	<0.001	<0.001
Teeth complete	80.3±1.48	66.5±1.54	52.9±2.04	0.001	<0.001
Periodontal pathogen IgG					
Phase 2	(N=895)	(N=914)	N=1,826)		
P. gingivalis					
Continuous	109.2±6.34	105.2±4.2	122.3±7.55	0.49	0.16
Log_e transformed	4.49±0.03	4.47±0.02	4.51±0.02	0.30	0.64
A. Actinomycetemcomitans (Aa)					
Continuous	99.3±5.53	102.8±5.15	94.5±2.87	0.66	0.39
Log_e transformed	4.45±0.03	4.46±0.02	4.44±0.02	0.79	0.61
Both Phases, Log_e transformed[c]	(N=1.622–1,692)	(N=1,617–1685)	(N=3,116–3,227)		
P. Gingivalis (Pg) mix	5.7±0.1	5.6±0.1	5.6±0.1	0.44	0.34
P. Intermedia (Pi)	5.6±0.1	5.5±0.1	5.3±0.0	0.57	0.002

	Age group (y)				
P. Nigrescens (Pn)	5.3±0.1	5.2±0.1	5.2±0.1	0.20	0.06
T. Forsythia (Tf)	4.8±0.1	4.7±0.1	4.7±0.1	0.37	0.76
A. Actinomycetemcomitans (Aa) mix	6.7±0.1	6.7±0.1	6.6±0.1	0.65	0.41
F. Nucleatum (Fn)	4.4±0.1	4.4±0.1	4.4±0.1	0.78	0.15
S. Oralis (So)	4.3±0.1	4.3±0.1	4.2±0.1	0.64	0.54
M. Micros (Mm)	5.2±0.1	5.2±0.1	5.1±0.1	0.52	0.13
C. Rectus (Cr)	4.4±0.1	4.3±0.1	4.4±0.1	0.11	0.73
E. Corrodens (Ec)	5.2±0.1	5.2±0.1	5.3±0.1	0.63	0.15
E. Nodatum (En)	7.3±0.1	7.1±0.1	6.8±0.1	0.09	<0.001
S. Intermedius (Si)	5.2±0.1	5.1±0.1	5.0±0.1	0.68	0.002
C. Ochracea (Co)	5.0±0.1	4.8±0.1	4.7±0.0	0.052	0.002
V. Parvula (Vp)	3.6±0.1	3.7±0.1	3.8±0.1	0.97	0.021
A. Naeslundii (An)	6.1±0.1	5.9±0.1	5.7±0.1	0.10	<0.001
P. Melaninogenica (Pm)	5.3±0.1	5.4±0.1	5.4±0.1	0.99	0.35
S. Noxia (Sn)	3.7±0.2	3.6±0.1	3.5±0.1	0.21	0.21
T. Denticola (Td)	4.9±0.1	4.8±0.1	4.8±0.1	0.35	0.43
S. Mutans (Sm)	4.5±0.1	4.5±0.1	4.4±0.1	0.82	0.40
Socio-demographic characteristics	(N=1,701)	(N=1,698)	(N=3,251)		
Age (years)	49.1±0.11	59.3±0.09	73.6±0.24	<0.001	<0.001
Sex, % male	48.5±1.75	44.8±1.12	41.4±1.12	0.07	0.002
Race/ethnicity	(N=1,701)	(N=1,698)	(N=3,251)		
Non-Hispanic White	79.7±1.80	79.0±2.06	86.6±1.30	—	—
Non-Hispanic Black	8.8±0.74	9.6±0.90	7.3±0.76	0.39	0.04
Mexican-American	4.3±0.43	2.9±0.31	1.9±0.17	0.003	<0.001
Other	7.3±1.46	8.5±1.97	4.3±0.85	0.54	0.02
Urban/rural area of residence	(N=1,701)	(N=1,698)	(N=3,251)		
Urban	50.1±4.69	46.1±4.53	43.2±5.11	0.18	0.06
Rural	49.1±4.69	53.9±4.53	56.8±5.11	—	—
	(N=1,701)	(N=1,698)	(N=3,251)		
Household size	2.9±0.06	2.5±0.04	1.9±0.03	<0.001	<0.001
Marital status	(N=1,701)	(N=1,698)	(N=3,251)		
Never married	5.4±0.97	3.1±0.43	4.0±0.41	0.02	0.93
Married	73.7±2.12	71.8±1.5	54.9±1.45	—	—
Divorced	13.7±1.72	10.4±1.06	5.4±0.57	0.14	0.003
Widowed	2.3±0.39	9.7±0.9	33.3±1.17	<0.001	<0.001
Other	4.8±0.61	4.9±0.85	2.5±0.39	0.82	0.08

Abbreviations: 25(OH)D=25-hydroxyvitamin D; AD=Alzheimer's Disease; EU=ELISA units; HEI=Healthy Eating Index; HS=High School; IgG=Immunoglobulin G; MAR=Mean Adequacy Ratio; NHANES=National Health and Nutrition Examination Surveys.

[a] Values are weighted means ± SEM or percent ± SEP, taking into account sampling design complexity (PSU and strata), across 5 imputations with 10 iterations.

[b] Design-based F-test accounting for design complexity in terms of sampling weights, PSU and stratum. for categorical variables, this was the equivalent of a χ^2 test of independence restricting the sample first to 55–64/45–54, then to 65+/45–54. For continuous variables, it was the

equivalent of a Wald test in a linear regression model with the variable being the outcome predicted by age group and in which 45–54y was the referent category to which “55–64” and “65+” were compared.

[c] SD of Log_e transformed periodontal pathogens across groups ranged between 1.2–1.3 (*Co*, *Vp*) and 1.8–2.0 (*Pg, En, An*), with the remaining ranging between 1.4 and 1.6.

TABLE 2.

P. gingivalis and *A. actinomycetemcomitans* serum IgG's association with incident all-cause and Alzheimer's Disease (AD) dementia and with AD mortality in multiple Cox proportional hazards model, overall and stratified by sex and race: NHANES III, 1991–1994[a]

	z-scored periodontal pathogen IgG (Phase II)[b]			z-scored , Log_e transformed periodontal pathogen IgG (Phase II)[b]		
	Log_e(HR)	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**
All-cause dementia [c]						
Men (N= 1,646)						
P. gingivalis	−0.19	(0.17)	0.31	−0.12	(0.10)	0.26
A. actinomycetemcomitans	+0.03	(0.06)	0.62	+0.03	(0.06)	0.66
Women (N= 1,979)						
P. gingivalis	+0.07	(0.07)	0.34	−0.04	(0.10)	0.69
A. actinomycetemcomitans	+0.05	(0.05)	0.36	+0.03	(0.07)	0.62
45+ at baseline (N=3,625)						
P. gingivalis	−0.01	0.11	0.92	−0.08	(0.06)	0.19
A. actinomycetemcomitans	+0.04	(0.04)	0.34	+0.03	(0.06)	0.60
55+ at baseline (N=2,731)						
P. gingivalis	+0.01	(0.09)	0.88	−0.08	(0.06)	0.21
A. actinomycetemcomitans	−0.01	(0.05)	0.91	−0.01	(0.05)	0.81
65+ at baseline (N=1,817)						
P. gingivalis	+0.04	(0.07)	0.59	−0.06	(0.06)	0.33
A. actinomycetemcomitans	***+0.12***	***(0.06)***	***0.051***	+0.08	(0.06)	0.19
AD dementia [d]						
Men (N= 1,646)						
P. gingivalis	−0.05	(0.21)	0.81	−0.11	(0.12)	0.37
A. actinomycetemcomitans	+0.10	(0.11)	0.34	+0.11	(0.11)	0.34
Women (N= 1,979)						
P. gingivalis	**+0.13**	**(0.04)**	**0.004****	+0.04	(0.06)	0.58
A. actinomycetemcomitans	−0.03	(0.11)	0.81	−0.09	(0.11)	0.40
45+ at baseline (N=3,625)						
P. gingivalis	**+0.06**	**(0.03)**	**0.034**	−0.04	(0.06)	0.50
A. actinomycetemcomitans	+0.01	(0.06)	0.84	−0.00	(0.07)	0.95
55+ at baseline (N=2,731)						
P. gingivalis	**+0.06**	**(0.02)**	**0.015****	−0.03	(0.06)	0.64
A. actinomycetemcomitans	−0.04	(0.08)	0.62	−0.07	(0.07)	0.28
65+ at baseline (N=1,817)						
P. gingivalis	**+0.11**	**(0.03)**	**0.003****	+0.03	(0.07)	0.72
A. actinomycetemcomitans	+0.07	(0.07)	0.35	+0.02	(0.07)	0.73
AD mortality [e]						
45+ at baseline (N=3,625)						

	z-scored periodontal pathogen IgG (Phase II)[b]			z-scored , Log_e transformed periodontal pathogen IgG (Phase II)[b]		
	Log_e(HR)	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**
P. gingivalis	+0.11	(0.07)	0.13	+0.14	(0.14)	0.31
A. actinomycetemcomitans	−0.03	(0.34)	0.94	−0.27	(0.30)	0.31
55+ at baseline (N=2,731)						
P. gingivalis	+0.09	(0.06)	0.13	+0.16	(0.14)	0.27
A. actinomycetemcomitans	−0.02	(0.35)	0.95	−0.33	(0.36)	0.38
65+ at baseline (N=1,817)						
P. gingivalis	+0.19	(0.15)	0.21	**+0.35**	**(0.15)**	**0.033** *
A. actinomycetemcomitans	**−2.61**	**(0.73)**	**0.002** **	**−1.23**	**(0.28)**	**<0.001** **

Abbreviations: 25(OH)D=25-hydroxyvitamin D; AD=Alzheimer's Disease; EU=ELISA units; HEI=Healthy Eating Index; HR=Hazard Ratio; HS=High School; IgG=Immunoglobulin G; MAR=Mean Adequacy Ratio; NHANES=National Health and Nutrition Examination Surveys.

[a] Models were adjusted for age, sex, race/ethnicity, poverty income ratio, education (years), urban-rural area of residence, household size, marital status, nutritional factors (HEI, MAR), nutritional biomarkers (25(OH)D, folate, vitamin C, vitamin A, total carotenoids, vitamin E, ferritin, selenium and normalized calcium), lifestyle (smoking, drug use, alcohol, physical activity), health-related factors (self-rated health, co-morbidity index, allostatic load, weight status), dentate status and social support variables. Covariates (other than exposures) were imputed and analysis is across 5 imputations with 10 iterations.

[b] Standardized into z-scores. 1 SD of untransformed Pg is 434 (45+), 148 (55+), 276 (65+), 605 (Men), 212 (Women); 1 SD of untransformed Aa is 87 (45+), 82 (55+), 72 (65+),85 (Men), 88 (Women). 1 SD of Log_e transformed Pg is ~0.85–0.90 for all groups; 1 SD of Log_e transformed Aa is ~0.85–0.90 for all groups

[c] 997 unweighted incident dementia cases for 45+, weighted mean follow-up time: 185 months.

[d] 503 unweighted incident AD cases for 45+, weighted mean follow-up time: 189 months.

[e] 52 unweighted AD deaths for 45+, weighted mean follow-up time: 192 months.

* P<0.033, marginally significant after correction for multiple testing;

** P<0.016, significant after correction for multiple testing.

TABLE 3.

Periodontal pathogens' serum IgG association with AD mortality in multiple Cox proportional hazards model, overall and restricted by baseline age group and sex: NHANES III, 1988–1994[a,b]

	≥45y[c]			≥55y[d]			≥65y[e]			Men[f]			Women[g]		
	Log_e(HR)	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**
AD mortality															
P. Gingivalis mix															
Model 1	+0.14	(0.13)	0.88	+0.15	(0.14)	0.28	**+0.35**	**(0.17)**	**0.046**	+0.25	(0.30)	0.40	+0.02	(0.25)	0.93
Model 2	+0.15	(0.10)	0.16	+0.17	(0.11)	0.13	**+0.31**	**(0.11)**	**0.010****	+0.33	(0.20)	0.11	−0.02	(0.13)	0.87
P. Intermedia															
Model 1	−0.08	(0.25)	0.74	−0.14	(0.27)	0.61	−0.19	(0.32)	0.57	+0.11	(0.52)	0.84	−0.04	(0.38)	0.93
Model 2	+0.20	(0.14)	0.15	+0.19	(0.13)	0.16	**+0.29**	**(0.13)**	**0.026***	+0.02	(0.14)	0.86	+0.11	(0.19)	0.58
P. Nigrescens															
Model 1	+0.18	(0.20)	0.36	+0.28	(0.21)	0.20	+0.18	(0.29)	0.54	−0.10	(0.66)	0.87	+0.10	(0.26)	0.69
Model 2	***+0.22***	***(0.13)***	***0.085***	***+0.25***	***0.13***	***0.063***	**+0.33**	**(0.14)**	**0.023***	**+0.43**	**(0.21)**	**0.049**	+0.11	(0.11)	0.46
T. Forsythia															
Model 1	***+0.43***	***(0.22)***	***0.058***	***+0.41***	***(0.21)***	***0.060***	+0.39	(0.25)	0.13	+0.86	(0.57)	0.14	**+0.64**	**(0.26)**	**0.019***
Model 2	+0.23	(0.14)	0.10	+0.22	(0.14)	0.12	**+0.34**	**(0.16)**	**0.036**	**+0.49**	**(0.22)**	**0.031***	+0.13	(0.17)	0.43
A. Actinomycetemcomitans (Aa) mix															
Model 1	−0.38	(0.26)	0.15	***−0.48***	***(0.27)***	***0.078***	−0.71	(0.45)	0.12	−0.05	(0.35)	0.88	**−0.80**	**(0.38)**	**0.039**
Model 2	−0.03	(0.15)	0.82	−0.10	(0.15)	0.52	−0.02	(0.19)	0.92	**+0.59**	**(0.28)**	**0.042**	−0.31	(0.20)	0.12
F. Nucleatum															
Model 1	−0.08	(0.28)	0.77	−0.04	(0.28)	0.89	+0.26	(0.35)	0.46	−0.77	(0.48)	0.12	+0.17	(0.40)	0.68
Model 2	+0.03	(0.13)	0.84	+0.02	(0.13)	0.86	+0.18	(0.14)	0.18	***+0.38***	***(0.19)***	***0.053***	−0.04	(0.16)	0.78
S. Oralis															
Model 1	+0.10	(0.26)	0.69	+0.03	(0.26)	0.90	+0.14	(0.31)	0.66	**+1.14**	**(0.46)**	**0.019***	−0.29	(0.29)	0.32
Model 2	+0.05	(0.13)	0.72	+0.02	(0.13)	0.87	+0.16	(0.13)	0.22	**+0.64**	**(0.25)**	**0.014****	−0.16	(0.16)	0.31
M. Micros															
Model 1	+0.21	(0.19)	0.29	+0.17	(0.20)	0.41	−0.20	(0.24)	0.39	−0.34	(0.32)	0.29	+0.42	(0.28)	0.15

	≥45y[c]			≥55y[d]			≥65y[e]			Men[f]			Women[g]		
	Log_e(HR)	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**
Model 2	+0.15	(0.10)	0.16	+0.10	(0.12)	0.42	+0.07	(0.14)	0.64	+0.19	(0.21)	0.38	+0.13	(0.14)	0.35
C. Rectus															
Model 1	−0.13	(0.18)	0.49	−0.03	(0.19)	0.89	−0.11	(0.26)	0.69	−0.80	(0.52)	0.13	+0.02	(0.22)	0.91
Model 2	+0.07	(0.12)	0.57	+0.01	(0.16)	0.96	+0.23	(0.14)	0.10	+0.18	(0.22)	0.42	−0.04	(0.14)	0.76
E. Corrodens															
Model 1	+0.12	(0.30)	0.68	−0.01	(0.28)	0.98	+0.27	(0.35)	0.44	−0.13	(0.39)	0.74	+0.13	(0.38)	0.74
Model 2	+0.08	(0.18)	0.67	+0.02	(0.17)	0.90	+0.19	(0.15)	0.23	+0.29	(0.24)	0.23	−0.02	(0.24)	0.92
E. Nodatum															
Model 1	−0.01	(0.19)	0.96	−0.01	(0.21)	0.98	+0.15	(0.22)	0.50	−0.51	(0.40)	0.21	−0.12	(0.31)	0.71
Model 2	+0.06	(0.17)	0.73	+0.02	(0.17)	0.90	+0.20	(0.19)	0.31	***+0.32***	***(0.19)***	***0.094***	−0.12	(0.25)	0.64
S. Intermedius															
Model 1	−0.09	(0.24)	0.71	−0.23	(0.23)	0.33	−0.11	(0.31)	0.72	+0.93	(0.37)	0.78	−0.35	(0.32)	0.28
Model 2	+0.04	(0.12)	0.72	−0.02	(0.12)	0.88	+0.15	(0.15)	0.33	**+0.72**	**(0.21)**	**0.001** **	−0.19	(0.16)	0.26
C. Ochracea															
Model 1	+0.08	(0.17)	0.64	+0.10	(0.18)	0.56	+0.07	(0.23)	0.76	+0.10	(0.34)	0.78	−0.04	(0.22)	0.86
Model 2	+0.05	(0.13)	0.72	+0.06	(0.14)	0.68	+0.09	(0.17)	0.58	+0.21	(0.16)	0.19	−0.08	(0.17)	0.61
V. Parvula															
Model 1	−0.13	(0.28)	0.65	+0.02	(0.25)	0.93	−0.10	(0.29)	0.73	+0.08	(0.41)	0.85	−0.06	(0.32)	0.85
Model 2	+0.06	(0.14)	0.68	+0.02	(0.16)	0.91	+0.17	(0.15)	0.26	***+0.46***	***(0.23)***	***0.051***	−0.10	(0.18)	0.58
A. Naeslundii															
Model 1	+0.03	(0.18)	0.89	−0.02	(0.19)	0.92	−0.04	(0.23)	0.86	+0.57	(0.51)	0.27	−0.06	(0.21)	0.77
Model 2	+0.04	(0.16)	0.80	+0.22	(0.14)	0.12	+0.11	(0.19)	0.57	**+0.48**	**(0.20)**	**0.020** *	−0.18	(0.21)	0.39
P. Melaninogenica															
Model 1	+0.30	(0.21)	0.17	+0.36	(0.22)	0.11	**+0.55**	**(0.19)**	**0.005** **	+0.20	(0.38)	0.59	+0.42	(0.27)	0.12
Model 2	+0.20	(0.13)	0.14	+0.22	(0.14)	0.12	**+0.36**	**(0.13)**	**0.009** **	**+0.41**	**(0.20)**	**0.047**	+0.15	(0.18)	0.40
S. Noxia															
Model 1	−0.15	(0.22)	0.50	−0.14	(0.22)	0.53	−0.14	(0.25)	0.57	−0.04	(0.32)	0.91	−0.34	(0.31)	0.28
Model 2	+0.02	(0.12)	0.87	+0.04	(0.13)	0.77	+0.13	(0.13)	0.31	***+0.37***	***(0.21)***	***0.092***	−0.16	(0.17)	0.36
T. Denticola															

	≥45y[c]			≥55y[d]			≥65y[e]			Men[f]			Women[g]		
	Log_e(HR)	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**
Model 1	−0.10	(0.25)	0.68	−0.06	(0.24)	0.79	−0.18	(0.25)	0.48	−0.15	(0.32)	0.64	−0.03	(0.32)	0.92
Model 2	−0.09	(0.13)	0.49	−0.09	(0.13)	0.49	−0.05	(0.13)	0.70	+0.17	(0.25)	0.50	−0.13	(0.18)	0.48
S. Mutans															
Model 1	−0.26	(0.23)	0.27	−0.26	(0.24)	0.30	−0.19	(0.27)	0.49	−0.40	(0.29)	0.18	+0.03	(0.27)	0.90
Model 2	−0.07	(0.13)	0.59	−0.08	(0.13)	0.52	+0.02	(0.14)	0.86	***+0.35***	***(0.19)***	***0.074***	−0.22	(0.16)	0.17

Abbreviations: AD=Alzheimer's Disease; BMI=Body Mass Index; HR=Hazard Ratio; HS=High School; IgG=Immunoglobulin G; NHANES=National Health and Nutrition Examination Surveys.

[a]Models were adjusted for age, sex, race/ethnicity, poverty income ratio, education (years), urban-rural area of residence, household size, marital status, nutritional factors (HEI, MAR), nutritional biomarkers (25(OH)D, folate, vitamin C, vitamin A, total carotenoids, vitamin E, ferritin, selenium and normalized calcium), lifestyle (smoking, drug use, alcohol, physical activity), health-related factors (self-rated health, co-morbidity index, allostatic load, weight status), dentate status and social support variables, as well as Phase of NHANES III. Covariates (other than exposures) were imputed and analysis is across 5 imputations with 10 iterations. Model 1: adjusted for all other periodontal pathogens; Model 2: one periodontal pathogen at a time.

[b]Periodontal pathogen exposures were Log_e transformed and then standardized into z-scores.

[c]Unweighted N=6,277–6,581, weighted mean follow-up time: 200 months;

[d]Unweighted N=4,681–4,912, weighted mean follow-up time=177 months;

[e]Unweighted N=3,077–3,229, weighted mean follow-up time: 148 months;

[f]Unweighted N=2,924–3,088, weighted mean follow-up time: 196 months

[g]Unweighted N=3,353–3,517, weighted mean follow-up time: 205 months.

[*]P<0.033, marginally significant after correction for multiple testing;

[**]P<0.016, significant after correction for multiple testing.

TABLE 4.

Periodontal pathogens' serum IgG (Factor scores and pre-defined clusters) association with AD mortality, AD incidence and all-cause dementia incidence in multiple Cox proportional hazards model, overall and restricted by baseline age group and sex: NHANES III, 1988–1994[a,b]

	≥45y[c]			≥55y[d]			≥65y[e]			Men[f]			Women[g]		
	Log_e(HR)	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**
Factor scores															
AD mortality															
Factor 1: So/Sm/Ec	−0.12	(0.16)	0.48	−0.23	(0.15)	0.14	−0.08	(0.17)	0.61	+0.56	(0.40)	0.17	−0.30	(0.24)	0.24
Factor 2:Pi/Pn/Pm	***+0.26***	***(0.14)***	***0.073***	**+0.31**	**(0.15)**	**0.043**	**+0.38**	**(0.15)**	**0.017****	+0.43	(0.29)	0.15	+0.19	(0.20)	0.35
Factor 3:An/En	+0.06	(0.19)	0.75	+0.02	(0.19)	0.90	+0.13	(0.23)	0.58	***+0.44***	***(0.24)***	***0.081***	−0.14	(0.27)	0.35
Factor 4:Pg/Cr	+0.12	(0.14)	0.40	+0.16	(0.15)	0.31	+0.19	(0.16)	0.24	−0.29	(0.28)	0.30	+0.16	(0.16)	0.32
Factor 5:Co/Sn	+0.04	(0.18)	0.82	***+0.23***	***(0.13)***	***0.081***	+0.18	(0.19)	0.34	−0.44	(0.39)	0.27	+0.17	(0.24)	0.48
AD incidence															
Factor 1: So/Sm/Ec	+0.06	(0.06)	0.34	+0.00	(0.07)	0.97	+0.06	(0.08)	0.48	+0.08	(0.14)	0.57	+0.08	(0.07)	0.25
Factor 2:Pi/Pn/Pm	+0.01	(0.05)	0.92	+0.01	(0.05)	0.86	+0.02	(0.06)	0.80	−0.00	(0.13)	1.00	−0.03	(0.07)	0.25
Factor 3:An/En	−0.08	(0.06)	0.20	−0.10	(0.06)	0.14	−0.11	(0.07)	0.13	−0.06	(0.11)	0.59	−0.10	(0.08)	0.25
Factor 4:Pg/Cr	+0.10	(0.06)	0.14	+0.11	(0.07)	0.11	**+0.20**	**(0.08)**	**0.012****	+0.12	(0.15)	0.44	**+0.17**	**(0.08)**	**0.038**
Factor 5:Co/Sn	−0.06	(0.09)	0.49	−0.02	(0.10)	0.83	−0.02	(0.12)	0.89	−0.05	(0.14)	0.72	−0.06	(0.09)	0.52
All-cause dementia incidence															
Factor 1: So/Sm/Ec	***+0.10***	***(0.05)***	***0.062***	+0.06	(0.05)	0.28	***+0.09***	***(0.05)***	***0.073***	+0.11	(0.09)	0.22	***+0.10***	***(0.06)***	***0.073***
Factor 2:Pi/Pn/Pm	−0.05	(0.04)	0.23	−0.03	(0.04)	0.55	−0.02	(0.04)	0.70	+0.02	(0.08)	0.83	***−0.10***	***(0.06)***	***0.070***
Factor 3:An/En	−0.07	(0.04)	0.15	−0.06	(0.04)	0.19	−0.07	(0.05)	0.16	−0.04	(0.08)	0.66	−0.08	(0.06)	0.17
Factor 4:Pg/Cr	+0.02	(0.05)	0.67	+0.04	(0.05)	0.39	+0.09	(0.06)	0.12	−0.10	(0.11)	0.33	+0.06	(0.06)	0.32
Factor 5:Co/Sn	−0.09	(0.06)	0.13	−0.06	(0.06)	0.39	−0.05	(0.07)	0.48	−0.15	(0.09)	0.10	−0.02	(0.07)	0.72
Pre-defined clusters															
AD mortality															
Cluster 1: Orange-Red	**+0.36**	**(0.16)**	**0.031***	**+0.44**	**(0.18)**	**0.016****	**+0.56**	**(0.17)**	**0.002****	+0.46	(0.47)	0.34	+0.29	(0.27)	0.28
Cluster 2: Red-Green	−0.22	(0.30)	0.47	−0.20	(0.31)	0.54	−0.16	(0.32)	0.61	−0.41	(0.75)	0.59	−0.18	(0.35)	0.61
Cluster 3: Yellow-Orange	+0.01	(0.20)	0.97	−0.07	(0.21)	0.73	−0.09	(0.25)	0.72	+0.38	(0.42)	0.37	−0.06	(0.23)	0.81
Cluster 4: Orange-Blue	+0.05	(0.18)	0.79	+0.01	(0.18)	0.94	+0.11	(0.22)	0.63	+0.34	(0.24)	0.16	−0.15	(0.26)	0.55

	≥45y[c]			≥55y[d]			≥65y[e]			Men[f]			Women[g]		
	Log_e(HR)	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**	**Log_e(HR)**	**(SE)**	**P**
AD incidence															
Cluster 1: Orange-Red	+0.02	(0.07)	0.75	+0.05	(0.08)	0.52	+0.05	(0.09)	0.57	−0.04	(0.14)	0.79	−0.00	(0.09)	0.99
Cluster 2: Red-Green	+0.16	(0.10)	0.12	+0.14	(0.09)	0.12	***+0.22***	***(0.11)***	***0.052***	−0.17	(0.21)	0.40	**+0.30**	**(0.13)**	**0.028** *
Cluster 3: Yellow-Orange	−0.12	(0.09)	0.21	***−0.16***	***(0.09)***	***0.093***	−0.16	(0.12)	0.16	+0.22	(0.16)	0.19	***−0.22***	***(0.13)***	***0.092***
Cluster 4: Orange-Blue	−0.08	(0.06)	0.19	−0.08	(0.06)	0.17	−0.10	(0.06)	0.11	−0.05	(0.10)	0.64	−0.10	(0.08)	0.21
All-cause dementia incidence															
Cluster 1: Orange-Red	−0.05	(0.06)	0.37	−0.03	(0.06)	0.64	−0.04	(0.06)	0.53	+0.02	(0.10)	0.86	−0.11	(0.08)	0.15
Cluster 2: Red-Green	+0.12	(0.07)	0.11	***+0.12***	***(0.07)***	***0.083***	***+0.15***	***(0.09)***	***0.092***	−0.15	(0.15)	0.33	**+0.21**	**(0.09)**	**0.018** *
Cluster 3: Yellow-Orange	−0.05	(0.06)	0.44	−0.07	(0.06)	0.22	−0.04	(0.09)	0.64	+0.14	(0.13)	0.25	−0.08	(0.10)	0.43
Cluster 4: Orange-Blue	−0.06	(0.04)	0.18	−0.05	(0.04)	0.21	−0.07	(0.04)	0.64	−0.02	(0.07)	0.79	−0.08	(0.05)	0.16

Abbreviations: See Table 1 for periodontal pathogen abbreviations. AD=Alzheimer's Disease.

[a]Models were adjusted for age, sex, race/ethnicity, poverty income ratio, education (years), urban-rural area of residence, household size, marital status, nutritional factors (HEI, MAR), nutritional biomarkers (25(OH)D, folate, vitamin C, vitamin A, total carotenoids, vitamin E, ferritin, selenium and normalized calcium), lifestyle (smoking, drug use, alcohol, physical activity), health-related factors (self-rated health, co-morbidity index, allostatic load, weight status), dentate status and social support variables, as well as Phase of NHANES III. Covariates (other than exposures) were imputed and analysis is across 5 imputations with 10 iterations.

[b]19 Periodontal pathogen exposures (both phases) were Log_e transformed and then standardized into z-scores. Factor analysis was conducted from which 5 factors were extracted each explaining >4% of total variance. After varimax rotation, factor 1 loaded highest (λ>0.40) on *T. forsythia* (0.68), *A. actinomycetemcomitans* (0.65*), F. nucleatum* (0.53), *S. oralis* (0.81), *M. micros* (0.51), *C. rectus* (0.54), *E. corrodens* (0.68), *S. intermedius* (0.63), *V. parvula* (0.64), *S. noxia* (0.62), *T. denticola* (0.63) and *S. mutans* (0.73); factor 2 on *P. gingivalis* (0.42), *P. itermedia* (0.85), *P. nigrescens* (0.84*), F. nucleatum* (0.44), *C. rectus* (0.40), *S. intermedius* (0.42), C. *ochracea*(0.44), *P. melaninogenica* (0.70) ; factor 3 on *E. nodatum* (0.75), *A. naselundii* (0.76); factor 4 on *P. gingivalis* (0.44) and *C. rectus* (0.42); and factor 5 on C. *ochracea* (0.45) and *S. noxia* (0.41). Factors were labelled based on up to 3 highest loadings, using a shortcut name for each. See Figure S1 and methods section for definition of each cluster.

[c]Unweighted N=6,277–6,278, weighted mean follow-up time: 200 months (AD mortality), 197 months (AD incidence), 192 months (all-cause dementia);

[d]Unweighted N=4,681–4,682, weighted mean follow-up time: 177 months (AD mortality), 171 months (AD incidence), 165 months (all-cause dementia);

[e]Unweighted N=3,077, weighted mean follow-up time: 148 months (AD mortality) , 141 months (AD incidence), 133 months (all-cause dementia) ;

[f]Unweighted N=2,924, weighted mean follow-up time: 196 months (AD mortality), 193 months (AD incidence), 189 months (all-cause dementia)

[g]Unweighted N=3,353–3,354, weighted mean follow-up time: 205 months (AD mortality), 200 months (AD incidence), 194 months (all-cause dementia).

*P<0.033, marginally significant after correction for multiple testing;

**P<0.016, significant after correction for multiple testing.